SCHEMBL6766930

SCHEMBL6766930

Cn1c(N2CCN(CCCCC3(C(=O)NCc4ccc(F)cc4)c4ccccc4-c4ccccc43)CC2)nc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
PKM P14618 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
CHRM1 P11229 2/20 0.42
CYP2D6 P10635 2/20 0.42
HRH1 P35367 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
TP53 P04637 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
KCNH2 Q12809 2/20 0.40
MTTP P55157 2/20 0.40
CHRM2 P08172 1/20 0.40
ADRA2A P08913 1/20 0.40
ADORA3 P0DMS8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6771866 0.94 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2TP53RXFP1DRD3
SCHEMBL6771800 0.94 ALDH1A1 (0.43) ALDH1A1LMNAHTTPKMSMN1; SMN2
SCHEMBL6770753 0.93 KMT2A (0.51) ALDH1A1LMNAPKMKMT2AMEN1
SCHEMBL6770137 0.91 CCR5 (0.41) ALDH1A1LMNACHRM1HRH1TP53
SCHEMBL6771329 0.90 ALDH1A1 (0.49) ALDH1A1LMNASLC6A2HTR1AHTR7
SCHEMBL6771032 0.88 ALDH1A1 (0.46) ALDH1A1LMNAHTTSMN1; SMN2KMT2A
SCHEMBL7596191 0.88 ALDH1A1 (0.49) ALDH1A1LMNAHTTPKMSMN1; SMN2
SCHEMBL6766832 0.87 PKM (0.44) ALDH1A1LMNAHTTPKMSMN1; SMN2
SCHEMBL6769807 0.87 MTTP (0.54) CHRM1KCNH2MTTPCHRM2ADRA2A
SCHEMBL6777257 0.86 ALDH1A1 (0.45) ALDH1A1CHRM1KCNH2MTTPCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6821967-B2 AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-11-23 US disclosed
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments MTTP, CETP, CPT1A ALDH1A1 715/4885LMNA 950/4885HTT 3935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.